Developing biomarker arrays predicting sleep and circadian-coupled risks to health

Janet M. Mullington; Sabra M. Abbott; Judith E. Carroll; Christopher J. Davis; Derk Jan Dijk; David F. Dinges; Philip R. Gehrman; Geoffrey S. Ginsburg; David Gozal; Monika Haack; Diane C. Lim; Madalina Macrea; Allan I. Pack; David T. Plante; Jennifer A. Teske; Phyllis C. Zee

doi:10.5665/sleep.5616

Developing biomarker arrays predicting sleep and circadian-coupled risks to health

Janet M. Mullington^*, Sabra M. Abbott, Judith E. Carroll, Christopher J. Davis, Derk Jan Dijk, David F. Dinges, Philip R. Gehrman, Geoffrey S. Ginsburg, David Gozal, Monika Haack, Diane C. Lim, Madalina Macrea, Allan I. Pack, David T. Plante, Jennifer A. Teske, Phyllis C. Zee

^*Corresponding author for this work

Neurology

Research output: Contribution to journal › Article › peer-review

84 Scopus citations

Abstract

The impact of advances in sleep and circadian sciences over the last 20 years on medicine, health, and public safety has been limited in part by the lack of availability of objective tools capable of quantifying sleep and circadian function in point-of-care (p-o-c) settings. This whitepaper is a product of a workshop that was designed to bring together thoughtleaders in biomarker development, experts in sleep-circadian biology and sleep disorders to identify barriers and opportunities informing the future development of p-o-c diagnostic tools. The workshop entitled, "Developing Biomarker Arrays Predicting Sleep and Circadian-Coupled Risks to Health," was held in Bethesda April 27-28 2015, and was jointly sponsored by the National Heart Lung and Blood Institute, National Institute on Aging and the Sleep Research Society (hereafter referred to as the biomarker workshop, (http:// www.nhlbi.nih.gov/research/reports). The Sleep Research Society supported a number of early career investigators to attend the workshop. They contributed to the writing of this whitepaper. A biomarker is a "biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, condition or disease."1,2 For the purpose of this whitepaper, "biomarkers" include quantifiable molecules and chemical properties of easily accessible biological samples (e.g., blood, urine, saliva). An ultimate goal is the development of robust and practical approaches for p-o-c or contact implementation in population-based research and most importantly, for clinical applications to enhance sleep and circadian health.

Original language	English (US)
Pages (from-to)	727-736
Number of pages	10
Journal	Sleep
Volume	39
Issue number	4
DOIs	https://doi.org/10.5665/sleep.5616
State	Published - Apr 1 2016

Funding

The National Heart Lung and Blood Institute (NHLBI) and the National Institute of Aging (NIA) jointly sponsored the meeting on which this whitepaper is based in partnership with the Sleep Research Society. The authors acknowledge the contributions of Drs. Michael Twery (NHLBI), Miroslaw Mackiewicz (NIA), and Karen Teff of the National Institutes of Diabetes and Digestive and Kidney Diseases through the scientific discussion of programmatic opportunities and meeting organization under the aegis of the National Institutes of Health. The authors also acknowledge the biomarker and additional sleep and circadian experts who participated in the meeting and breakout groups including: Ronald G. Crystal, Weill Cornell Medical College Karyn A. Esser, University of Kentucky Joshua J. Gooley, Duke-National University of Singapore Graduate Medical School Alfred Hero, The University of Michigan John B. Hogenesch, University of Pennsylvania M.Mahmood Hussain, SUNY Downstate Medical Center Rima Kaddurah-Daouk, Duke University School of Medicine Satchindananda Panda, The Salk Institute Peipei Ping, UCLA School of Medicine Virend Somers, Mayo Clinic Russell Tracy, The University of Vermont Martin Young, University of Alabama School of Medicine

ASJC Scopus subject areas

General Medicine

Access to Document

10.5665/sleep.5616

Cite this

Mullington, J. M., Abbott, S. M., Carroll, J. E., Davis, C. J., Dijk, D. J., Dinges, D. F., Gehrman, P. R., Ginsburg, G. S., Gozal, D., Haack, M., Lim, D. C., Macrea, M., Pack, A. I., Plante, D. T., Teske, J. A., & Zee, P. C. (2016). Developing biomarker arrays predicting sleep and circadian-coupled risks to health. Sleep, 39(4), 727-736. https://doi.org/10.5665/sleep.5616

@article{999f2429825f4a1d9f4835276e0ff9c9,

title = "Developing biomarker arrays predicting sleep and circadian-coupled risks to health",

abstract = "The impact of advances in sleep and circadian sciences over the last 20 years on medicine, health, and public safety has been limited in part by the lack of availability of objective tools capable of quantifying sleep and circadian function in point-of-care (p-o-c) settings. This whitepaper is a product of a workshop that was designed to bring together thoughtleaders in biomarker development, experts in sleep-circadian biology and sleep disorders to identify barriers and opportunities informing the future development of p-o-c diagnostic tools. The workshop entitled, {"}Developing Biomarker Arrays Predicting Sleep and Circadian-Coupled Risks to Health,{"} was held in Bethesda April 27-28 2015, and was jointly sponsored by the National Heart Lung and Blood Institute, National Institute on Aging and the Sleep Research Society (hereafter referred to as the biomarker workshop, (http:// www.nhlbi.nih.gov/research/reports). The Sleep Research Society supported a number of early career investigators to attend the workshop. They contributed to the writing of this whitepaper. A biomarker is a {"}biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, condition or disease.{"}1,2 For the purpose of this whitepaper, {"}biomarkers{"} include quantifiable molecules and chemical properties of easily accessible biological samples (e.g., blood, urine, saliva). An ultimate goal is the development of robust and practical approaches for p-o-c or contact implementation in population-based research and most importantly, for clinical applications to enhance sleep and circadian health.",

author = "Mullington, {Janet M.} and Abbott, {Sabra M.} and Carroll, {Judith E.} and Davis, {Christopher J.} and Dijk, {Derk Jan} and Dinges, {David F.} and Gehrman, {Philip R.} and Ginsburg, {Geoffrey S.} and David Gozal and Monika Haack and Lim, {Diane C.} and Madalina Macrea and Pack, {Allan I.} and Plante, {David T.} and Teske, {Jennifer A.} and Zee, {Phyllis C.}",

year = "2016",

month = apr,

day = "1",

doi = "10.5665/sleep.5616",

language = "English (US)",

volume = "39",

pages = "727--736",

journal = "Sleep",

issn = "0161-8105",

publisher = "Oxford University Press",

number = "4",

}

TY - JOUR

T1 - Developing biomarker arrays predicting sleep and circadian-coupled risks to health

AU - Mullington, Janet M.

AU - Abbott, Sabra M.

AU - Carroll, Judith E.

AU - Davis, Christopher J.

AU - Dijk, Derk Jan

AU - Dinges, David F.

AU - Gehrman, Philip R.

AU - Ginsburg, Geoffrey S.

AU - Gozal, David

AU - Haack, Monika

AU - Lim, Diane C.

AU - Macrea, Madalina

AU - Pack, Allan I.

AU - Plante, David T.

AU - Teske, Jennifer A.

AU - Zee, Phyllis C.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - The impact of advances in sleep and circadian sciences over the last 20 years on medicine, health, and public safety has been limited in part by the lack of availability of objective tools capable of quantifying sleep and circadian function in point-of-care (p-o-c) settings. This whitepaper is a product of a workshop that was designed to bring together thoughtleaders in biomarker development, experts in sleep-circadian biology and sleep disorders to identify barriers and opportunities informing the future development of p-o-c diagnostic tools. The workshop entitled, "Developing Biomarker Arrays Predicting Sleep and Circadian-Coupled Risks to Health," was held in Bethesda April 27-28 2015, and was jointly sponsored by the National Heart Lung and Blood Institute, National Institute on Aging and the Sleep Research Society (hereafter referred to as the biomarker workshop, (http:// www.nhlbi.nih.gov/research/reports). The Sleep Research Society supported a number of early career investigators to attend the workshop. They contributed to the writing of this whitepaper. A biomarker is a "biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, condition or disease."1,2 For the purpose of this whitepaper, "biomarkers" include quantifiable molecules and chemical properties of easily accessible biological samples (e.g., blood, urine, saliva). An ultimate goal is the development of robust and practical approaches for p-o-c or contact implementation in population-based research and most importantly, for clinical applications to enhance sleep and circadian health.

AB - The impact of advances in sleep and circadian sciences over the last 20 years on medicine, health, and public safety has been limited in part by the lack of availability of objective tools capable of quantifying sleep and circadian function in point-of-care (p-o-c) settings. This whitepaper is a product of a workshop that was designed to bring together thoughtleaders in biomarker development, experts in sleep-circadian biology and sleep disorders to identify barriers and opportunities informing the future development of p-o-c diagnostic tools. The workshop entitled, "Developing Biomarker Arrays Predicting Sleep and Circadian-Coupled Risks to Health," was held in Bethesda April 27-28 2015, and was jointly sponsored by the National Heart Lung and Blood Institute, National Institute on Aging and the Sleep Research Society (hereafter referred to as the biomarker workshop, (http:// www.nhlbi.nih.gov/research/reports). The Sleep Research Society supported a number of early career investigators to attend the workshop. They contributed to the writing of this whitepaper. A biomarker is a "biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, condition or disease."1,2 For the purpose of this whitepaper, "biomarkers" include quantifiable molecules and chemical properties of easily accessible biological samples (e.g., blood, urine, saliva). An ultimate goal is the development of robust and practical approaches for p-o-c or contact implementation in population-based research and most importantly, for clinical applications to enhance sleep and circadian health.

UR - http://www.scopus.com/inward/record.url?scp=84962476806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962476806&partnerID=8YFLogxK

U2 - 10.5665/sleep.5616

DO - 10.5665/sleep.5616

M3 - Article

C2 - 26951388

AN - SCOPUS:84962476806

SN - 0161-8105

VL - 39

SP - 727

EP - 736

JO - Sleep

JF - Sleep

IS - 4

ER -

Developing biomarker arrays predicting sleep and circadian-coupled risks to health

Abstract

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this